A TREATMENT OPTION FOR ADULTS WITH PREVIOUSLY TREATED HER2+ ADVANCED STOMACH CANCER
VIEW CLINICAL TRIAL RESULTS
In a clinical study of 188 people with previously treated HER2+ advanced stomach cancer, ENHERTU helped people live longer than with chemotherapy.* Among people in the trial, half of the people taking ENHERTU were alive at 12.5 months. For people taking chemotherapy, half of the people were alive at 8.4 months.† This was about 4 months longer with ENHERTU.
In the same clinical study, tumors shrank in more people treated with ENHERTU than with chemotherapy*‡:
- 40.5% (51 of 126) of people saw a confirmed response with ENHERTU and 11.3% (7 of 62) did with chemotherapy‡§
- 7.9% (10 of 126) of people taking ENHERTU achieved a complete response, meaning their tumor could not be seen on imaging tests. This does not always mean the cancer has been cured. No one taking chemotherapy (0 of 62) had a complete response
- 32.5% (41 of 126) of people taking ENHERTU achieved a partial response, which means the tumor shrank by at least 30%. 11.3% (7 of 62) of those taking chemotherapy had a partial response
- 84% (106 of 126) of people taking ENHERTU saw their tumors shrink, stop growing, or the growth of their tumors slowed, and 61% (38 of 62) of people saw this while receiving chemotherapyll
https://www.enhertu.com/en/gastric